New eye drug faricimab tested for blinding disease
NCT ID NCT07581782
First seen May 13, 2026 · Last updated Jun 20, 2026 · Updated 9 times
Summary
This study will test the drug faricimab, given as eye injections, in 50 people with wet age-related macular degeneration (nAMD). The goal is to see if it improves vision and eye health. Participants will receive 4 initial doses, then more as needed. The study is observational, meaning there is no comparison group, and it has not yet started recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
faricimab (eye injection)
What this could lead to
If successful, this could show that faricimab helps stabilize or improve vision in people with wet age-related macular degeneration.
What could go wrong
This is a small, early observational study with no comparison group. Results may not apply to all patients, and faricimab may not work as well in real-world settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.